- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Darryl Sleep: Identifying and Treating Elevated LDL-C in Patients Can Mitigate Heart Attack Risk
Identifying elevated LDL-C levels in patients and treating them with evolocumab can potentially mitigate and reduce the rate of ischemic events, said Darryl Sleep, MD, senior vice president, global medical and chief medical officer at Amgen.
Identifying elevated LDL-C levels in patients and treating them with evolocumab can potentially mitigate and reduce the rate of ischemic events, said Darryl Sleep, MD, senior vice president for global medical and chief medical officer at Amgen.
Transcript
Can you discuss the significance of the evolocumab FOURIER clinical trial findings and their impact on patients in lowering high LDL-C and subsequent risk of myocardial infarction?
Patients post-myocardial infarction are at significant risk for developing additional ischemic heart disease or myocardial infarction. This is 1 of those areas where it's been clearly identified as a risk factor, and LDL-C is an easily measured biomarker that clearly demonstrates increased risk as well. So, what we've done in the FOURIER study is really identify in this analysis those patients that have had a recent myocardial infarction within the first year of the infarction with elevated LDL-C that number 1, the closer you are to the index event, the more likely you are to have a subsequent event. Elevated LDL-C clearly puts you at risk for that subsequent event and [through] aggressive treatment of patients with elevated LDL-C in that setting, you can actually mitigate, reduce the events, and the rate of events in those patients. So, perfect interface between identifiable marker in patients at risk, a treatment option that can lower LDL-C significantly, and importantly, that reduces the event that you're seeking to prevent.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
